Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes

被引：0
作者：
Sennik, Devesh [1 ]
Ahmed, Fahad [1 ]
Russell-Jones, David [1 ]
机构：
[1] Royal Surrey Cty Hosp, CEDAR Ctr, Diabet & Endocrine Dept, Guildford GU2 7XX, Surrey, England
来源：
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2012年 / 7卷 / 01期
关键词：
diabetes mellitus; duration studies; exenatide; GLP-1; incretin; Type; 2; diabetes;
D O I：
10.1586/EEM.11.79
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Incretin-based therapies represent a new and innovative treatment modality in the management of Type 2 diabetes. Their therapeutic actions address many of the key metabolic defects in the pathophysiology of diabetes. Incretin hormones augment insulin secretion in a glucose-dependent manner. They have a low risk of inducing hypoglycemia, unlike many other antidiabetic medications. They also have the beneficial effect of being associated with early satiety, decreased caloric intake and weight loss. Exenatide was the first incretin-based therapy to be licensed for use and has now been developed in a once-weekly preparation. We review the evidence base for the use of exenatide and discuss the implications for the management of diabetes.
引用
收藏
页码：15 / 26
页数：12
相关论文
共 50 条
  • [21] Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications
    Lesven, S.
    Gautier, J. -F.
    Marechaud, R.
    ANNALES D ENDOCRINOLOGIE, 2010, 71 (06) : 505 - 510
  • [22] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [23] Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
    Aung, Myo Myo
    Slade, Kate
    Freeman, Leighton A. R.
    Kos, Katarina
    Whatmore, Jacqueline L.
    Shore, Angela C.
    Gooding, Kim M.
    DIABETOLOGIA, 2019, 62 (09) : 1701 - 1711
  • [24] Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus
    Lahey, Alexa M.
    Duprey, Karolyn
    Montague, Riley C.
    Schadler, Aric D.
    Naseman, Kristina W.
    PHARMACOTHERAPY, 2025, : 220 - 226
  • [25] The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
    Aroda, Vanita R.
    Ratner, Robert
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (06) : 528 - 542
  • [26] A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
    Montanya, Eduard
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1451 - 1467
  • [27] The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes
    van der Klauw, M. M.
    Wolffenbuttel, B. H. R.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (10) : 436 - 443
  • [28] The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes
    Tee, Su Ann
    Tsatlidis, Vasileios
    Razvi, Salman
    CLINICAL ENDOCRINOLOGY, 2023, 99 (04) : 401 - 408
  • [29] GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
    Nauck, Michael A.
    Quast, Daniel R.
    Wefers, Jakob
    Meier, Juris J.
    MOLECULAR METABOLISM, 2020, 46
  • [30] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETOLOGIA, 2016, 59 (07) : 1412 - 1421
12345